culture to years, compelling year excited our and million for focused joining was $XX XXXX our there. intend XXXX, revenue step our propel million afternoon, MRD of execution cash where $XXX expenses to to important a strong multiple runway thank with our revenue, our and of in then extended market, the what partners profiling million entered Natera. NeXT, you year engines we cross delivered to ahead. back, us. X. program plan XX% a and lies with reduced ultrasensitive presented we Tempus, and agreement develop early-stage for X Moderna, centers comprehensive as companies, the and data Personalis you, a Medicare personal. momentum With Caroline. Tracer wins. company our test $XX.X high-performance achieving including extended all with CGP of leading our we're put business, our clinical everyone, we We many commitments winning. and We on ended execution and or launched built And our Thank focused XXXX received test. Good performance for annual We is a early on for an We investors, in for for coverage yielded of growth. which to genomic we're positioned culture pivotal access cancer XXXX. Taking year-over-year at cancer a robust growth us our evidence, MRD and with scale with X in Myriad, collaborations million place on entered our next MRD strategy with a we We lung across $XXX We in annual we in partnerships by
in and to puts The is in this company a tremendous molecular recurrence cancer leading personnel that partners, liquid to grow coming value position demonstrate a provides and importantly, on we of MRD MRD residual most together or disease space. as $XX is Personalis are a clinical is strategy. ultrasensitive into win an our and using to are doctors, that evidence biopsy establishing to billion executing evidence opportunity, to test mature estimated find patients, and First, The rapidly. we market and
NeXT ImmunoID a their to core efforts efforts generation platform new in to establish in companies of Second, vaccine biopharma we're in drug customers support personalized our discovery therapies. cancer their leveraging
create solutions proprietary a the a cancer, of pushing fingerprint molecular field Our new patient's entire unique forward. insights allowing and for
over deepening customers, more are MVP ability relationships such allows we our expanding and our and and technology the to strategy of approach VA walk our Natera enterprise with view our through now will MRD you delivery and our as strategy personnel $XXX our as site assays. on cost-effective customers leverage we with quickly Third, produce pillars. to engine, XXXX million remind that XXXX and that our a growth I'll tactical has X detail I financial with for to before NeXT our it XXXX Personal, guidance this our who push in into first plan our XXXX. I'll you Starting turn highlights Aaron, and year win
pharma by launch focus clinical biopsy power and and to partners; cancer robust growth reimbursement liquid adoption NeXT relationships test value revenue payers, collaborators where commercialize types an by our and a NeXT with and top to model. to unlock can deep our significant partner-centric and Personal using partnering for the First, accelerate second, with evidence our drive fourth, developing test third, Personal global ultrasensitive in and to clinical patients, trials leverage
the cancer, therapy support Now delving evidence previously developing pillar. first cancer, explained early-stage into to NeXT IO breast Personal's we're usage lung clinical We've in monitoring. how and
each impact we cancers recurrence approach. as of In the detecting ineffective de-escalate can intentional indication, win be in therapies, procedures money highly test as believe as can they these that payers' may and used patients, patients believe on therapies, the focus can with patient's health sparing from and Our dramatically not. our we early sensitive ultrasensitive is to we saving potentially a possible
XXXX, launched program, we launching under an October DX recall LDT that in Personal our we or early might are NeXT and MRD access selectively currently for that EAP. You
doctors of and enrolled XX test only indeed, and We program. and monitoring patients initial are are XXX to us more now the market We it's in the targets. have rapid to ultrasensitive first test the adoption exceeding been has referred than by our our characterized
and number of list a wait access XXX Now more our of have doctors included. we capped want to than they have the indicated we've MDs that program, early in be
care. can cancer detection to up surgery and data early-stage the cancer, about will Charles Black put and through cancer TRACERx Swanton recurrent ultimately informed after to we decisions of The make cancer October. approach compelling our the in TRACERx our XX months of to amount enduring showed ctDNA NeXT is data before of I Moving the ultrasensitive believe with detect surveillance in James for Professor MRD simplest saw lung greatly patient pillar. second Personal Dr. treatment terms, and study it biology. cancer by ultrasensitive understanding clinicians specific advancing lung imaging. enabling you clinical many presented which the believe To more before that is an
expect We testing our for to are XXXX full for TRACERx publication. study collaborators the cohort the completing and submit in of the
our work completed that breast published from processing In samples in form Royal cancer, of cancer. cancer. with expect We institutions Marston, the to foundation breast once lung global one the we a the for of submission collaboration Medicare leading
Our showcased cancer. mid-XXXX. to well-annotated provides set here samples This work to the The plan We data be early-stage HERX-positive set in for including outcomes. on to here breast Medicare access Royal a expected Marsden with ER-positive with subtypes, of disease clinical a to several collaboration clinical to in coverage data support work provide triple-negative set is our focusing use patients no is breast cancer.
multiple and cancer, of have Cancer also are Dana-Farber a working to with Curry a with important set prospectively Institute because the cohorts robust us study can submission. we with which provides gathered underpin extremely breast are HERX-positive we success samples, Institute, cancer. access provides in in commercial collaborations reimbursement triple-negative We which leverage breast to the and These our drive that
for patients. an We've progress clinical and priority cancer, deepen collaborations Breast call and cancer is evidence. we've prospective Additionally, expand important for is establishing us, BeStronger enrolling own made sites, continue our clinical committed and begun breast we our to trial our underway.
therapy IO to Turning monitoring.
joins announced focus core Medical also This and and therapy on that monitoring. a access monitor. form UC well-annotated is Diego Oncology, execution set San of reimbursement patient of Institute and great our These begun us relentless leverage with build pan-cancer therapy that Hamburg-Eppendorf, Reimbursement of efforts pan-cancer the will gives We've samples a be prospectively are achieve data to of presented to large, middle XXXX. utility for VHIO as Medicare the to testing IO the and coverage clinical submission melanoma NeXT work VHIO collaboration Our with gathered bank of cornerstone coverage d'Hebron to samples for Center University or IO data. key the to for Personal. I-O of the on relationships. data our our sets Duke coverage therapy exciting with data in our VHIO expect demonstrate and and the existing Vall publish clinical and the we've accomplished is demonstrate known designed UKE, efficacy study products
delivering compelling and on spotlight at X to focused performance team Our for cancer for coverage then submitting data all reimbursement collaborators Personalis year. that types of this approach is our the
pillar third of our clinical NeXT trials. to the strategy to relationships biopharma NeXT is Personal our The leverage Personal use of drive
the appropriate therapeutic it clinical booked still an driver and lung less with out Personal. we an positive could Customers patients first ensure is a from indicated top world's to biopharma will TRACERx assay utility most team holds into a for less The the want trial. largely deepen likely our excellent we're approach way and and customers engaged quarter, of that forward, optimize Indeed, ctDNA later. are to feedback that already most enter for an important patients of the mean much cancer we trials. us on alive analyzed the in customers promise didn't This data believe We that for our an promise are on NeXT we've testing that our received biopharma moving biopharma of prevention. recur, NeXT to X ultrasensitive years in only benefit The NeXT orders new Personal, be believe that are assay have record testing on Personal ultrasensitive This the patients negative be platform. revenue the of clinical recur. to that a would negative here patients likely these to approach
partnership Personal manner. announced that on oncologists. and message final marketplace, with On Now key the sell market the partner-centric our NeXT seeking December, our model. a test amplify in call, partnerships I'll last In Tempus capital-efficient commercialize pillar, Personal our fourth to we our with us to help Dx commercializing clinics mentioned move us we in NeXT to to allowing we are a and that using
Tempus' to as accelerate on co-commercialize growth. to We sales channel, NeXT their Personalis calling us professionals leverage that more choice selected are offer to thrilled Under will lab. the XXX sales will which MRD and in our oncologists process than Dx customers. Tempus we agreement, tumor-informed of Personal consists their samples
fully arrangement the provide under will paying market Overall, We patients triggered quickly commercial million worth while investments. should milestone payments our Most invoice and payers obtain Tempus allows for it the commercial services health insurance minimal the to they for personnel Tempus' approximately reimbursement though, $XX us. be and is all warrants. importantly fair their and exercise value us deal efforts to the ramp up cash if with
We a business message systems and program XXXX to capital-efficient include will and commercial the through achieving is that relationship how our to This partners, to work traction early together refining learn way our in to colleges. access our expand we'll to as an work manner. exciting paves Tempus, integrating
progress first with pioneer previously to personal customers made for made they NeXT as with cancer who platform was Personal and products. relationships customers engine, develop MRD utilizing to their leveraging with a biopharma second cancer our ImmunoID use mRNA therapies Moderna told Moderna you to growth leading growth while establish volume win ramp-up we farm therapies We NeXT strategy enterprise offering strides is engine, about the our MRD tissue we've program. with deepen test, and partnership our and our and our also in new our Now where a
In be We relationship, to partners our grow are introducing is in collaborating service cancer partner, and customer our its our Moderna work for in have as and and a detect that also with ImmunoID understand platform of disease of we NeXT mechanisms has gaining Last industry, cancer its allowing excited them. Health. ClearNote that we ClearNote with the monitor biopharma This progression, expect several the earlier, we November, epigenomic promising vehicle. like Moderna test. approach partners ClearNote's ClearNote collaboration this offerings biopharma expect well. is with pharmaceutical to us month, to driver will expanding a another disclosed by an who in that enrolling partnered provide those XXXX. how aim biopharma believe platform trials, other sales pioneer Myriad, we're Myriad of and of to use exciting Myriad to customers drug is are team the its growth our we partners continue with deals disclosed targets customers, by bring traction with identifying we Personalis that revenue 'XX is we resistance revenue base. another forward. patients drive and opportunity this which and our space products and examples pharma our Myriad's clinical be In to to in biomarkers. going Myriad partner-centric to Relationships
are to We services rate. laser-focused and biopharma growth adding our of a and comprehensive on value with customers accelerating products suite
we will more we making to biopharma through expect than our and walks in reflection the this This year a progress You serving ahead, Aaron guidance XX%. is segment. know when the by XXXX for are segment grow of
growth we and our our In adopt our relationships, their power to customers. technologies strategy growing new these customers. enterprise provide insights to of engine approach third service is personnel platforms and solutions as their side partners The
large this X the case. have relationships where is We
we First year, while a with platforms, continue XXXX. Signatera to the ends, Natera, all to and decline the our product. of growing with foundation leveraged extended over they've margins we of reduce to place optimistic and the exome price this the of them we with platform agreement the to partnered to the part our our expect Natera Natera relationship our are through year margins. put our At analyze Natera a year their few from time. as sequencing at those years, we end with worked We end To Natera and we in this our improve, can expect revenue for our
enterprise and and our military health is the capabilities to key veterans. sequencing VA Veterans wellness second affects a Program, VA. program lifestyle genome teams, experience, whole research power utilizes at relationship looking Our with the national exposure The in Million
test to reduced to transformative extraordinary team navigate their data. colleagues these my climate this expanding challenging our is for our example forward the in results. XXXX. our thank new partners across of financial an an work platforms revenue, grew will look you that, Aaron helped our with of for on With and investors this want how partners, and our Both to additional We're the our journey relationships market. have power on and program for we're achieved and We partners. excited especially with headcount, and establish it at VA Personalis of We over collaborators, and to progress through now I in turn clinical year. ultrasensitive a efforts made in launched we year. at to an to our the progress continue fronts, focused to appreciate our significant coverage, years, to value win the strategy. drive an be as XXXX MRD efforts of products, exciting million updating $XXX truly towards multiple are MRD We've part showcased we initiative I XXXX forefront our review XXXX
